These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 16018297)

  • 1. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables.
    Navarro RP; Parasuraman B
    Manag Care Interface; 2005 Jun; 18(6):31-40. PubMed ID: 16018297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and resource use of mild persistent asthma patients initiated on controller therapy.
    Colice GL; Yu AP; Ivanova JI; Hsieh M; Birnbaum HG; Lage MJ; Brewster C
    J Asthma; 2008 May; 45(4):293-9. PubMed ID: 18446593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ratio of controller to total asthma medications: determinants of the measure.
    Broder MS; Gutierrez B; Chang E; Meddis D; Schatz M
    Am J Manag Care; 2010 Mar; 16(3):170-8. PubMed ID: 20225912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considering therapeutic options in the real world.
    Martin RJ
    J Allergy Clin Immunol; 2003 Nov; 112(5 Suppl):S112-5. PubMed ID: 14586396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of risk factors and health outcomes among persons with asthma.
    Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
    J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma costs and utilization in a managed care organization.
    Zeiger RS; Hay JW; Contreras R; Chen W; Quinn VP; Seal B; Schatz M
    J Allergy Clin Immunol; 2008 Apr; 121(4):885-92.e5. PubMed ID: 18313133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD; Buxton M; Andersson LF; Lamm CJ; Liljas B; Chen YZ; Pauwels RA; Weiss KB
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary therapy in asthma: inhaled corticosteroids and what?
    Bjermer L; Diamant Z
    Curr Opin Pulm Med; 2009 Jan; 15(1):46-51. PubMed ID: 19077705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroids.
    Dorais M; Blais L; Chabot I; LeLorier J
    J Asthma; 2005 Jun; 42(5):385-93. PubMed ID: 16036414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study.
    Weiss K; Buxton M; Andersson FL; Lamm CJ; Liljas B; Sullivan SD
    Pediatr Allergy Immunol; 2006 May; 17 Suppl 17():21-7. PubMed ID: 16573705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based pharmacologic treatment for mild asthma.
    Koh MS; Irving LB
    Int J Clin Pract; 2007 Aug; 61(8):1375-9. PubMed ID: 17590220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults.
    Altawalbeh SM; Thorpe CT; Zgibor JC; Kane-Gill S; Kang Y; Thorpe JM
    J Manag Care Spec Pharm; 2018 May; 24(5):478-486. PubMed ID: 29694289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthma and allergy medication use and costs among pediatric primary care patients on asthma controller therapy.
    Sazonov-Kocevar V; Laforest L; Travier N; Yin DD; Van Ganse E
    Pediatr Allergy Immunol; 2006 Dec; 17(8):620-8. PubMed ID: 17121591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
    Peters SP; Ferguson G; Deniz Y; Reisner C
    Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early intervention of recent onset mild persistent asthma in children aged under 11 yrs: the Steroid Treatment As Regular Therapy in early asthma (START) trial.
    Chen YZ; Busse WW; Pedersen S; Tan W; Lamm CJ; O'Byrne PM
    Pediatr Allergy Immunol; 2006 May; 17 Suppl 17():7-13. PubMed ID: 16573703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.